Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy
Sepsis represents a systemic inflammatory response caused by microbial infection in blood. Herein, we present a novel comprehensive approach to mitigate inflammatory responses through broad spectrum removal of pathogens, leukocytes and cytokines based on biomimetic cell margination. Using a murine m...
| Main Authors: | , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Royal Society of Chemistry, The
2017
|
| Online Access: | http://hdl.handle.net/1721.1/110938 https://orcid.org/0000-0003-3150-6170 https://orcid.org/0000-0001-7215-1439 |
| _version_ | 1826208389293670400 |
|---|---|
| author | Hou, Han Wei Wu, Lidan Amador-Munoz, Diana P. Vera, Miguel Pinilla Coronata, Anna Englert, Joshua A. Levy, Bruce D. Baron, Rebecca M. Han, Jongyoon |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Hou, Han Wei Wu, Lidan Amador-Munoz, Diana P. Vera, Miguel Pinilla Coronata, Anna Englert, Joshua A. Levy, Bruce D. Baron, Rebecca M. Han, Jongyoon |
| author_sort | Hou, Han Wei |
| collection | MIT |
| description | Sepsis represents a systemic inflammatory response caused by microbial infection in blood. Herein, we present a novel comprehensive approach to mitigate inflammatory responses through broad spectrum removal of pathogens, leukocytes and cytokines based on biomimetic cell margination. Using a murine model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), we performed extracorporeal blood filtration with the developed microfluidic blood margination (μBM) device. Circulating bacteremia, leukocytes and cytokines in blood decreased post-filtration and significant attenuation of immune cell and cytokine responses were observed 3–5 days after intervention, indicating successful long-term immunomodulation. A dose-dependent effect on long-term immune cell count was also achieved by varying filtration time. As proof of concept for human therapy, the μBM device was scaled up to achieve ∼100-fold higher throughput (∼150 mL h⁻¹). With further multiplexing, the μBM technique could be applied in clinical settings as an adjunctive treatment for sepsis and other inflammatory diseases. |
| first_indexed | 2024-09-23T14:04:40Z |
| format | Article |
| id | mit-1721.1/110938 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T14:04:40Z |
| publishDate | 2017 |
| publisher | Royal Society of Chemistry, The |
| record_format | dspace |
| spelling | mit-1721.1/1109382022-10-01T19:03:27Z Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy Hou, Han Wei Wu, Lidan Amador-Munoz, Diana P. Vera, Miguel Pinilla Coronata, Anna Englert, Joshua A. Levy, Bruce D. Baron, Rebecca M. Han, Jongyoon Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science Massachusetts Institute of Technology. Research Laboratory of Electronics Hou, Han Wei Wu, Lidan Han, Jongyoon Sepsis represents a systemic inflammatory response caused by microbial infection in blood. Herein, we present a novel comprehensive approach to mitigate inflammatory responses through broad spectrum removal of pathogens, leukocytes and cytokines based on biomimetic cell margination. Using a murine model of polymicrobial sepsis induced by cecal ligation and puncture (CLP), we performed extracorporeal blood filtration with the developed microfluidic blood margination (μBM) device. Circulating bacteremia, leukocytes and cytokines in blood decreased post-filtration and significant attenuation of immune cell and cytokine responses were observed 3–5 days after intervention, indicating successful long-term immunomodulation. A dose-dependent effect on long-term immune cell count was also achieved by varying filtration time. As proof of concept for human therapy, the μBM device was scaled up to achieve ∼100-fold higher throughput (∼150 mL h⁻¹). With further multiplexing, the μBM technique could be applied in clinical settings as an adjunctive treatment for sepsis and other inflammatory diseases. United States. Defense Advanced Research Projects Agency (N66001-11-1-4182) 2017-08-14T14:34:14Z 2017-08-14T14:34:14Z 2016-01 2015-09 Article http://purl.org/eprint/type/JournalArticle 1473-0197 1473-0189 http://hdl.handle.net/1721.1/110938 Hou, Han Wei, et al. “Broad Spectrum Immunomodulation Using Biomimetic Blood Cell Margination for Sepsis Therapy.” Lab on a Chip 16, 4 (2016): 688–699 © 2016 The Royal Society of Chemistry https://orcid.org/0000-0003-3150-6170 https://orcid.org/0000-0001-7215-1439 en_US http://dx.doi.org/10.1039/c5lc01110h Lab on a Chip Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Royal Society of Chemistry, The PMC |
| spellingShingle | Hou, Han Wei Wu, Lidan Amador-Munoz, Diana P. Vera, Miguel Pinilla Coronata, Anna Englert, Joshua A. Levy, Bruce D. Baron, Rebecca M. Han, Jongyoon Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy |
| title | Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy |
| title_full | Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy |
| title_fullStr | Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy |
| title_full_unstemmed | Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy |
| title_short | Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy |
| title_sort | broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy |
| url | http://hdl.handle.net/1721.1/110938 https://orcid.org/0000-0003-3150-6170 https://orcid.org/0000-0001-7215-1439 |
| work_keys_str_mv | AT houhanwei broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy AT wulidan broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy AT amadormunozdianap broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy AT veramiguelpinilla broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy AT coronataanna broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy AT englertjoshuaa broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy AT levybruced broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy AT baronrebeccam broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy AT hanjongyoon broadspectrumimmunomodulationusingbiomimeticbloodcellmarginationforsepsistherapy |